<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>De Tommasi O</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Ovarian carcinosarcoma (OCS), also known as malignant mixed Müllerian tumor, is a rare and highly aggressive subtype of epithelial ovarian cancer, accounting for less than 4% of all cases. It typically presents at advanced stages and is associated with dismal outcomes, with a five-year survival rate below 30%. Despite improvements in cytoreductive surgery and systemic therapies, long-term survival in stage IV disease remains exceedingly uncommon.&lt;h4>Case presentation&lt;/h4>We report two exceptional cases of stage IVB Müllerian carcinosarcoma occurring in BRCA wild-type postmenopausal women who achieved prolonged complete remission exceeding five years after multimodal management. The first patient, aged 61, presented with bilateral adnexal masses and a solitary pulmonary m</pubmed_abstract><journal>Frontiers in oncology</journal><pagination>1728398</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12827093</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Stage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission.</pubmed_title><pmcid>PMC12827093</pmcid><pubmed_authors>Massa D</pubmed_authors><pubmed_authors>Noventa M</pubmed_authors><pubmed_authors>Saccardi C</pubmed_authors><pubmed_authors>Bigardi S</pubmed_authors><pubmed_authors>Nardin M</pubmed_authors><pubmed_authors>Tozzi R</pubmed_authors><pubmed_authors>Spagnol G</pubmed_authors><pubmed_authors>Guerriero A</pubmed_authors><pubmed_authors>De Tommasi O</pubmed_authors><pubmed_authors>Tasca G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Stage IVB ovarian carcinosarcoma in BRCA wild-type patients: two case reports of unexpected long-term remission.</name><description>&lt;h4>Background&lt;/h4>Ovarian carcinosarcoma (OCS), also known as malignant mixed Müllerian tumor, is a rare and highly aggressive subtype of epithelial ovarian cancer, accounting for less than 4% of all cases. It typically presents at advanced stages and is associated with dismal outcomes, with a five-year survival rate below 30%. Despite improvements in cytoreductive surgery and systemic therapies, long-term survival in stage IV disease remains exceedingly uncommon.&lt;h4>Case presentation&lt;/h4>We report two exceptional cases of stage IVB Müllerian carcinosarcoma occurring in BRCA wild-type postmenopausal women who achieved prolonged complete remission exceeding five years after multimodal management. The first patient, aged 61, presented with bilateral adnexal masses and a solitary pulmonary m</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-06T22:28:26.97Z</modification><creation>2026-06-06T03:10:31.629Z</creation></dates><accession>S-EPMC12827093</accession><cross_references><pubmed>41584593</pubmed><doi>10.3389/fonc.2025.1728398</doi></cross_references></HashMap>